Published in Clin Pharmacol Ther on May 01, 2003
Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet (2003) 2.18
Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol (2009) 1.51
The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol (2008) 1.26
ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol (2009) 1.13
Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol (2005) 1.05
Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II). Br J Clin Pharmacol (2004) 1.02
Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins. Eur J Clin Pharmacol (2014) 0.97
Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin J Am Soc Nephrol (2008) 0.97
Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol (2004) 0.94
Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity. Br J Clin Pharmacol (2006) 0.94
Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br J Clin Pharmacol (2007) 0.93
Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. J Clin Pharmacol (2010) 0.80
Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation. J Lipid Res (2013) 0.79
In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. Pharmacotherapy (2013) 0.78
Effects of chronic kidney disease on liver transport: quantitative intravital microscopy of fluorescein transport in the rat liver. Am J Physiol Regul Integr Comp Physiol (2014) 0.78
Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int J Clin Oncol (2007) 0.78
Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum. Clin Pharmacol (2013) 0.75
Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12. Clin Pharmacol Drug Dev (2016) 0.75
The pharmacokinetics and safety of darapladib in subjects with severe renal impairment. Br J Clin Pharmacol (2015) 0.75
Xenobiotic metabolism: the effect of acute kidney injury on non-renal drug clearance and hepatic drug metabolism. Int J Mol Sci (2014) 0.75
MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet (2008) 9.50
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet (2012) 6.69
APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med (2013) 5.00
Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol (2009) 4.16
Vascular access hemorrhages contribute to deaths among hemodialysis patients. Kidney Int (2012) 3.40
Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16
Chronic kidney disease adversely influences patient safety. J Am Soc Nephrol (2008) 2.93
Acute kidney injury and cardiovascular outcomes in acute severe hypertension. Circulation (2010) 2.76
The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med (2009) 2.76
Clinical practice. Stage IV chronic kidney disease. N Engl J Med (2010) 2.66
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. Am Heart J (2008) 2.61
The use and interpretation of quasi-experimental studies in infectious diseases. Clin Infect Dis (2004) 2.52
Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol (2005) 2.47
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med (2003) 2.45
Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis (2012) 2.42
The relationship between dialysis performance measures: adequacy and anemia management. Am J Kidney Dis (2007) 2.09
Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol (2009) 2.01
Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order amish. Arthritis Rheum (2008) 1.97
Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol (2002) 1.97
N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis (2005) 1.96
Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol (2008) 1.91
The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant (2001) 1.88
Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol (2005) 1.74
Renal function, erythropoietin, and anemia of older persons: the InCHIANTI study. Arch Intern Med (2005) 1.72
Critical and honest conversations: the evidence behind the "Choosing Wisely" campaign recommendations by the American Society of Nephrology. Clin J Am Soc Nephrol (2012) 1.69
A study of renal outcomes in obese living kidney donors. Transplantation (2010) 1.67
Genotype-based changes in serum uric acid affect blood pressure. Kidney Int (2011) 1.62
Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int (2011) 1.61
Drug interactions in transplant patients: what everyone should know. Curr Opin Nephrol Hypertens (2009) 1.57
Have we fallen off target with concerns surrounding dual RAAS blockade? Kidney Int (2010) 1.55
A prospective controlled study of kidney donors: baseline and 6-month follow-up. Am J Kidney Dis (2013) 1.55
Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections. J Clin Epidemiol (2006) 1.54
Transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers: Influence of size, charge and fluorescent labeling. Pharm Res (2006) 1.51
Development and validation of GFR-estimating equations using diabetes, transplant and weight. Nephrol Dial Transplant (2009) 1.46
Cigarette smoking, kidney function, and mortality after live donor kidney transplant. Am J Kidney Dis (2010) 1.45
BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin Transpl (2002) 1.43
Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev (2006) 1.42
Current status of kidney and pancreas transplantation in the United States, 1994-2003. Am J Transplant (2005) 1.37
Recent advances in the prevention and management of intradialytic hypotension. J Am Soc Nephrol (2008) 1.36
A comparison of change in measured and estimated glomerular filtration rate in patients with nondiabetic kidney disease. Clin J Am Soc Nephrol (2008) 1.29
The Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) study: rationale and methods. J Vasc Interv Radiol (2005) 1.28
Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med (2005) 1.24
The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. Int J Pharm (2002) 1.21
An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol (2006) 1.21
Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology (2013) 1.18
Prevalence of ocular fundus pathology in patients with chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.17
Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med (2013) 1.17
Retinopathy and chronic kidney disease in the Chronic Renal Insufficiency Cohort (CRIC) study. Arch Ophthalmol (2012) 1.16
Enaminones: Exploring additional therapeutic activities. J Pharm Sci (2007) 1.15
Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. J Pharm Sci (2007) 1.14
The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm Drug Dispos (2002) 1.12
Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) (2011) 1.12
Adverse safety events in chronic kidney disease: the frequency of "multiple hits". Clin J Am Soc Nephrol (2009) 1.11
A study of renal outcomes in African American living kidney donors. Transplantation (2009) 1.09
Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2012) 1.09
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis (2013) 1.08
Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes--the Stop Atherosclerosis in Native Diabetics Study (SANDS). Am Heart J (2006) 1.08
Preemptive renal transplantation: why not? Am J Transplant (2003) 1.07
Payment for quality in end-stage renal disease. J Am Soc Nephrol (2004) 1.07
Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women. Clin J Am Soc Nephrol (2011) 1.05
Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients. Clin J Am Soc Nephrol (2010) 1.05
Metabolic syndrome, components, and cardiovascular disease prevalence in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Nephrol (2011) 1.05
Predictors of compliance with antihypertensive therapy in a high-risk medicaid population. J Natl Med Assoc (2009) 1.05
Mechanism of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated mitochondrial dysfunction in rat liver. Proteomics (2008) 1.03
Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis (2008) 1.03
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. Eur J Heart Fail (2009) 1.00
Longitudinal association of depressive symptoms with rapid kidney function decline and adverse clinical renal disease outcomes. Clin J Am Soc Nephrol (2011) 1.00
Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. J Pharmacol Exp Ther (2003) 1.00
Reasons for discharges against medical advice: a qualitative study. Qual Saf Health Care (2010) 0.99
Drug therapy persistence and stroke recurrence. Am J Manag Care (2006) 0.98
Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. Am J Nephrol (2013) 0.97
Plant protein intake is associated with fibroblast growth factor 23 and serum bicarbonate levels in patients with chronic kidney disease: the Chronic Renal Insufficiency Cohort study. J Ren Nutr (2012) 0.97
Zonula occludens toxin increases the permeability of molecular weight markers and chemotherapeutic agents across the bovine brain microvessel endothelial cells. J Pharm Sci (2003) 0.97
Opioids and efflux transporters. Part 1: P-glycoprotein substrate activity of N-substituted analogs of meperidine. Bioorg Med Chem Lett (2006) 0.97
Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation. J Pharm Sci (2009) 0.97
Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int (2004) 0.97
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract (2016) 0.97
Red blood cell transfusion use in patients with chronic kidney disease. Nephrol Dial Transplant (2013) 0.96
Usability testing and acceptance of an electronic medication inquiry system for CKD patients. Am J Kidney Dis (2012) 0.96
Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm (2009) 0.96
The evolving role of mTOR inhibition in transplantation tolerance. J Am Soc Nephrol (2011) 0.96
The independent association between serum uric acid and graft outcomes after kidney transplantation. Transplantation (2010) 0.96
Salt intake and progression of chronic kidney disease: an overlooked modifiable exposure? A commentary. Am J Kidney Dis (2005) 0.96
Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor. Drug Metab Dispos (2009) 0.95
Usability of a CKD educational website targeted to patients and their family members. Clin J Am Soc Nephrol (2012) 0.95
Serum carboxymethyl-lysine, a dominant advanced glycation end product, is associated with chronic kidney disease: the Baltimore longitudinal study of aging. J Ren Nutr (2009) 0.94
The metabolic syndrome: a call to action. Coron Artery Dis (2006) 0.93
Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich) (2003) 0.92